The Artificial Intelligence-Derived Electrocardiographic Age Gap is Associated with Adverse Clinical Outcomes in Cardiac Laminopathy
Abstract Body (Do not enter title and authors here): Background: Disease-causative variants in LMNA-encoded lamin A/C cause the laminopathies, a heterogeneous group of diseases variably resulting in arrhythmogenic/dilated cardiomyopathy (ACM/DCM), lipodystrophy, muscular dystrophy, and progeria. The artificial intelligence (AI)-derived electrocardiographic age gap (AI-EAG), determined by the discrepancy between a patient’s artificial AI-enabled electrocardiogram (ECG) predicted biological age versus their chronological age, is accelerated in laminopathy. Thus, we sought to determine if the AI-EAG serves as a prognostic marker in patients with cardiac laminopathy. Methods: Retrospective analysis of 1,049 genotype-positive patients with genetic ACM/DCM was used to identify those with pathogenic/likely pathogenic (P/LP) variants in LMNA. After the exclusion of those who lacked a 12-lead ECG while in sinus rhythm, a previously trained AI-ECG age algorithm was used to determine the AI-EAG by subtracting the patient’s chronological age from the AI-ECG derived biological age. The AI-EAG was then correlated with a combined outcome of major ventricular arrhythmia [sudden cardiac arrest, sustained ventricular tachycardia, and appropriate implantable cardioverter-defibrillator shocks], heart transplantation, and cardiovascular death. Results: Overall, 147/1,049 (14%) patients with genetically-mediated ACM/DCM had a P/LP variant in LMNA. Of these, 80/147 (54%) LMNA variant-positive patients (52% female, mean chronological age 36 ± 15 years) had ECGs suitable for AI-EAG analysis. Most (52/80; 65%) had an AI-EAG >10 years with a mean AI-EAG of 17 ± 13 years. Of note, the AI-EAG was greater in those with a clinical cardiac phenotype (20 ± 14 vs. 13 ± 10 years; p = 0.011). As a continuous variable, an increased AI-EAG was associated with increased risk of the composite outcome at a median follow-up of 20 months (HR 1.036; 95% CI 1.004–1.068; p = 0.026) and AI-EAG > 10 and > 20 years were both associated with elevated risk (HR 4.272; 95% CI 1.388–13.147; p = 0.011 and HR 3.732; 95% CI 1.505–9.255; p = 0.004, respectively). Conclusion: In cardiac laminopathy, an increased AI-EAG was common and correlated with adverse cardiovascular outcomes. Non-invasive ascertainment of electrocardiographic aging by AI may provide a novel prognostic marker in cardiac laminopathy. Future studies are needed to validate this finding and further define the role of the AI-EAG in the risk-stratification of patients with cardiac laminopathy.
Castrichini, Matteo
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Ackerman, Michael
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Milone, Margherita
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Giudicessi, John
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Sularz, Agata
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Garmany, Ramin
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Tester, David
( MAYO CLINIC COLLEGE OF MEDICINE
, Rochester
, Minnesota
, United States
)
Bos, Johan
( Mayo Clinic College of Medicine
, Rochester
, Minnesota
, United States
)
Attia, Zachi
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Noseworthy, Peter
( MAYO CLINIC
, Rochester
, Minnesota
, United States
)
Friedman, Paul
( MAYO CLINIC
, Rochester
, Minnesota
, United States
)
Lopez-jimenez, Francisco
( MAYO CLINIC COLL MEDICINE
, Rochester
, Minnesota
, United States
)
Author Disclosures:
Matteo Castrichini:DO NOT have relevant financial relationships
| Michael Ackerman:DO have relevant financial relationships
;
Consultant:Abbott:Active (exists now)
; Royalties/Patent Beneficiary:UpToDate:Active (exists now)
; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now)
; Royalties/Patent Beneficiary:Solid Biosciences:Active (exists now)
; Royalties/Patent Beneficiary:Prolaio:Active (exists now)
; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now)
; Royalties/Patent Beneficiary:AliveCor:Active (exists now)
; Consultant:Tenaya Therapeutics:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Consultant:Invitae:Past (completed)
; Consultant:Illumina:Active (exists now)
; Consultant:Bristol Myers Squibb:Past (completed)
; Consultant:Boston Scientific:Active (exists now)
; Consultant:BioMarin Pharmaceutical:Past (completed)
| Margherita Milone:DO NOT have relevant financial relationships
| John Giudicessi:DO have relevant financial relationships
;
Consultant:Avidity Biosciences:Active (exists now)
; Consultant:Nuevocor Therapeutics:Active (exists now)
; Consultant:Citizen Health:Active (exists now)
| Agata Sularz:DO NOT have relevant financial relationships
| Ramin Garmany:DO NOT have relevant financial relationships
| David Tester:No Answer
| Johan Bos:DO NOT have relevant financial relationships
| Zachi Attia:No Answer
| Peter Noseworthy:DO have relevant financial relationships
;
Royalties/Patent Beneficiary:Anumana:Active (exists now)
| Paul Friedman:DO have relevant financial relationships
;
Other (please indicate in the box next to the company name):Anumana:Active (exists now)
; Other (please indicate in the box next to the company name):Eko Health:Active (exists now)
; Other (please indicate in the box next to the company name):AliveCor:Active (exists now)
| Francisco Lopez-Jimenez:DO have relevant financial relationships
;
Advisor:Novo Nordisk:Active (exists now)
; Other (please indicate in the box next to the company name):Up-To-Date Author of chapter:Active (exists now)
; Consultant:Regeneron:Active (exists now)
; Advisor:WizeHealth:Past (completed)
; Royalties/Patent Beneficiary:Anumana:Active (exists now)
; Consultant:New Amsterdam Pharma:Past (completed)
; Consultant:MediWhale:Past (completed)
; Researcher:Select Research:Past (completed)
; Consultant:K-Health:Active (exists now)
; Consultant:Kento Health:Active (exists now)
; Advisor:Anumana:Active (exists now)